Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation and Depletion (2017 - 2019)

Arrowhead Pharmaceuticals (ARWR) has disclosed Depreciation and Depletion for 3 consecutive years, with $578342.0 as the latest value for Q2 2019.

  • For the quarter ending Q2 2019, Depreciation and Depletion fell 23.0% year-over-year to $578342.0, compared with a TTM value of $2.9 million through Jun 2019, changed N/A, and an annual FY2018 reading of $3.0 million, changed 0.3% over the prior year.
  • Depreciation and Depletion was $578342.0 for Q2 2019 at Arrowhead Pharmaceuticals, down from $750860.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $803287.0 in Q3 2018 and bottomed at $578342.0 in Q2 2019.
  • Average Depreciation and Depletion over 3 years is $725756.1, with a median of $750860.0 recorded in 2019.
  • The sharpest move saw Depreciation and Depletion rose 5.05% in 2018, then fell 23.0% in 2019.
  • Year by year, Depreciation and Depletion stood at $716066.0 in 2017, then rose by 5.05% to $752245.0 in 2018, then dropped by 23.12% to $578342.0 in 2019.
  • Business Quant data shows Depreciation and Depletion for ARWR at $578342.0 in Q2 2019, $750860.0 in Q1 2019, and $752245.0 in Q4 2018.